Structural and Biophysical Characterization of C‐Glycosylic 1,2‐Thiodisaccharides Reveals Determinants of Selective Binding to Galectin‐7 and Galectin‐8N
ChemMedChem · 2026
DOI: 10.1002/cmdc.70439 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Anastasia S Tsagkarakou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Galectins, Disaccharides. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hungarian National Research, Development and Innovation Office.
Abstract (Originalsprache)
Achieving isoform selectivity within the galectin family remains a central challenge in glycomimetic drug design due to the highly conserved architecture of their carbohydrate recognition domains. Here, we define the structural and thermodynamic basis of recognition of a series of C‐glycosylic 1,2‐thiodisaccharides targeting human galectin‐7 and the N‐terminal domain of galectin‐8 (galectin‐8N). Using an integrated approach combining fluorescence polarization, isothermal titration calorimetry, and high‐resolution X‐Ray crystallography, we establish a clear structure–activity relationship across the ligand series. Compound 17 emerges as the most potent galectin‐8N ligand ( K d = 13 μM), outperforming thiodigalactoside, while compound 13 shows preferential binding to galectin‐7, demonstrating tunable isoform bias. Structural analysis reveals a conserved anchoring mechanism in which the β‐galactoside unit (Gly‐1) drives affinity through a rigid hydrogen‐bonding and π‐stacking network, whereas the second sugar (Gly‐2) modulates potency by adopting distinct orientations in galectin‐specific extended binding sites. Notably, ligand binding converges on conserved motifs while leaving nonconserved regions unexploited, highlighting clear opportunities for structure‐guided optimization. Collectively, this work establishes C‐glycosylic thiodisaccharides as a robust platform for selective galectin targeting and provides actionable design principles for next‐generation inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece.
- Department of Organic Chemistry, University of Debrecen, Debrecen, Hungary.
- Department of Biochemistry, Veterinary School, University of Thessaly, Karditsa, Greece.
- Department of Laboratory Medicine, Lund University, Lund, Sweden.
- Department of Chemistry, Lund University, Lund, Sweden.
ORCID-Profile: Anastasia S Tsagkarakou, Nikolaos Veliotis, László Juhász, Hakon Leffler, Ulf J Nilsson, László Somsák, Demetres D Leonidas
Förderung
- Hungarian National Research, Development and Innovation Office
Zitieren
APA
Tsagkarakou, A. S., Kantsadi, A. L., Theodoridou, V. I., Veliotis, N., Lázár, L., József, J., Juhász, L., Kontopidis, G., Leffler, H., Nilsson, U. J., Somsák, L., & Leonidas, D. D. (2026). Structural and Biophysical Characterization of C‐Glycosylic 1,2‐Thiodisaccharides Reveals Determinants of Selective Binding to Galectin‐7 and Galectin‐8N. ChemMedChem. https://doi.org/10.1002/cmdc.70439
Vancouver
Tsagkarakou AS, Kantsadi AL, Theodoridou VI, Veliotis N, Lázár L, József J, et al. Structural and Biophysical Characterization of C‐Glycosylic 1,2‐Thiodisaccharides Reveals Determinants of Selective Binding to Galectin‐7 and Galectin‐8N. ChemMedChem. 2026. doi:10.1002/cmdc.70439
BibTeX
@article{Tsagkarakou2026,
author = {Tsagkarakou, Anastasia S and Kantsadi, Anastassia L and Theodoridou, Vasiliki I and Veliotis, Nikolaos and Lázár, László and József, János and Juhász, László and Kontopidis, George and Leffler, Hakon and Nilsson, Ulf J and Somsák, László and Leonidas, Demetres D},
title = {Structural and Biophysical Characterization of C‐Glycosylic 1,2‐Thiodisaccharides Reveals Determinants of Selective Binding to Galectin‐7 and Galectin‐8N},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70439}
}
EUVIMED